E A C Wiemer - JoVE Visualize

Showing results (1-10 of 14) with videos related to

Pageof 2

Sort By:

Current Cancer Drug Targets|May 16, 2009

The applicability of mTOR inhibition in solid tumorsI R H M Konings, J Verweij, E A C Wiemer, et al.

Cellular and Molecular Life Sciences : CMLS|October 3, 2003

The vault complexA van Zon, M H Mossink, R J Scheper, et al.

British Journal of Cancer|November 27, 2008

The spliceosome as target for anticancer treatmentR J van Alphen, E A C Wiemer, H Burger, et al.

BJU International|June 8, 2004

Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximineJ P van Brussel, M A Oomen, P J M Vossebeld, et al.

Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007

Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.

Clinical Pharmacology and Therapeutics|February 22, 2008

Renal function as a predictor of irinotecan-induced neutropeniaF A de Jong, J M van der Bol, R H J Mathijssen, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 20, 2007

A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomyA G J Aalbers, M ten Kate, W M U van Grevenstein, et al.

British Journal of Cancer|April 16, 2002

Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault proteinG L Scheffer, A W Reurs, B Jutten, et al.

British Journal of Pharmacology|January 14, 2010

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)H Burger, A Zoumaro-Djayoon, A W M Boersma, et al.

Leukemia|May 3, 2002

Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)M M van den Heuvel-Eibrink, E A C Wiemer, A Prins, et al.

Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:

Pageof 2

Current Cancer Drug Targets|May 16, 2009

The applicability of mTOR inhibition in solid tumorsI R H M Konings, J Verweij, E A C Wiemer, et al.

Cellular and Molecular Life Sciences : CMLS|October 3, 2003

The vault complexA van Zon, M H Mossink, R J Scheper, et al.

British Journal of Cancer|November 27, 2008

The spliceosome as target for anticancer treatmentR J van Alphen, E A C Wiemer, H Burger, et al.

BJU International|June 8, 2004

Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007

Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.

Clinical Pharmacology and Therapeutics|February 22, 2008

Renal function as a predictor of irinotecan-induced neutropeniaF A de Jong, J M van der Bol, R H J Mathijssen, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 20, 2007

A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomyA G J Aalbers, M ten Kate, W M U van Grevenstein, et al.

British Journal of Cancer|April 16, 2002

Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault proteinG L Scheffer, A W Reurs, B Jutten, et al.

British Journal of Pharmacology|January 14, 2010

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)H Burger, A Zoumaro-Djayoon, A W M Boersma, et al.

Leukemia|May 3, 2002

Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)M M van den Heuvel-Eibrink, E A C Wiemer, A Prins, et al.

Pageof 2